共 196 条
[11]
Lichte T(2014)Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties Br J Pharmacol 171 3604-1155
[12]
Rudolf S(2005)Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade Psychopharmacology 177 448-566
[13]
Wiltink J(2015)Profile of agomelatine and its potential in the treatment of generalized anxiety disorder Neuropsychiatr Dis Treat 11 1149-1008
[14]
Beutel ME(2008)Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study J Clin Psychopharmacol 28 561-368
[15]
Bui E(2012)Agomelatine prevents relapse in generalised anxiety disorder: a 6-month placebo-controlled discontinuation study J Clin Psychiatry 73 1002-537
[16]
King F(2014)Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study J Clin Psychiatry 75 362-979
[17]
Melaragno A(2017)Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study Eur Neuropsychopharmacol 27 526-777
[18]
Craske MG(2018)12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50mg/day) versus escitalopram (10–20mg/day) in out-patients with severe generalized anxiety disorder Eur Neuropsychopharmacol 28 970-40
[19]
Stein MB(2019)Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis Lancet 393 768-95
[20]
Eley TC(2015)The impact of medication on health-related quality of life in patients with generalized anxiety disorder CNS Drugs 29 29-8